Van Trung Chu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Van Trung Chu has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Klaus Rajewsky
Program in Cellular and Molecular Medicine, Children’s Hospital, and Immune Disease Institute, Harvard Medical School, Boston, USA
11 shared publications Ngoc Tung Tran
Max Delbruck Ctr Mol Med Helmholtz Assoc MDC, Immune Regulat & Canc, Berlin, Germany
6 shared publications- Ralf Kühn
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
6 shared publications Janine Trombke
5 shared publications- Robin Graf
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
5 shared publications Klaus Rajewsky
Max Delbruck Ctr Mol Med Helmholtz Assoc MDC, Immune Regulat & Canc, Berlin, Germany
4 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Elsevier in Cell Reports Methods
A Cas9D10A nickase mouse line for precise genome editing
- 18 November 2026
- Published by Elsevier in Cell Reports Methods
Open AccessA Cas9D10A nickase mouse line for precise genome editing
- Open Access
Histone H3 Acetylation at Sox1ot Promoter by Targeted Epigenome Editing Augments Proliferation of Intermediate Progenitors in Developing Cortex
Factors regulating the genesis and expansion of basal progenitor cell sub-populations, including intermediate progenitor cells, are critical determinants of cortical neurogenesis and brain growth. Epigenetic (chromatin) marks have emerged as notable regulators of cortical development. However, it is unclear how these factors specifically interact in the epigenome to orchestrate brain development. Here, we combined in vivo electroporation and a CRISPR-dead (d)Cas9 system to probe the contribution of a specific histone modification mark, H3K9ac (H3K9 acetylation), in the epigenome of isolated intermediate progenitor cells in developing mouse cortices. CRISPR-dCas9-mediated addition of H3K9ac at the promoter region of lncRNA Sox1ot resulted in Sox1ot upregulation, with attendant increase in the intermediate progenitor pool and augmented neurogenesis. Thus, we found an interplay between H3K9ac and Sox1ot, which drives the amplification of cortical intermediate progenitor cell population. By targeting H3K9ac to the Sox1ot promoter, we were able to stimulate the proliferation of intermediate progenitor cells leading to enhanced cortical neurogenesis. In essence, we have identified H3K9ac as a key epigenetic regulator of Sox1ot expression, which may dynamically be involved in intermediate progenitor cell pool expansion during brain development and evolution.
Open AccessHistone H3 Acetylation at Sox1ot Promoter by Targeted Epigenome Editing Augments Proliferation of Intermediate Progenitors in Developing Cortex
Factors regulating the genesis and expansion of basal progenitor cell sub-populations, including intermediate progenitor cells, are critical determinants of cortical neurogenesis and brain growth. Epigenetic (chromatin) marks have emerged as notable regulators of cortical development. However, it is unclear how these factors specifically interact in the epigenome to orchestrate brain development. Here, we combined in vivo electroporation and a CRISPR-dead (d)Cas9 system to probe the contribution of a specific histone modification mark, H3K9ac (H3K9 acetylation), in the epigenome of isolated intermediate progenitor cells in developing mouse cortices. CRISPR-dCas9-mediated addition of H3K9ac at the promoter region of lncRNA Sox1ot resulted in Sox1ot upregulation, with attendant increase in the intermediate progenitor pool and augmented neurogenesis. Thus, we found an interplay between H3K9ac and Sox1ot, which drives the amplification of cortical intermediate progenitor cell population. By targeting H3K9ac to the Sox1ot promoter, we were able to stimulate the proliferation of intermediate progenitor cells leading to enhanced cortical neurogenesis. In essence, we have identified H3K9ac as a key epigenetic regulator of Sox1ot expression, which may dynamically be involved in intermediate progenitor cell pool expansion during brain development and evolution.
- Open Access
- 23 July 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (9) , 2003-2015
In vivo CRISPR/Cas9-mediated screen reveals a critical function of TFDP1 and E2F4 transcription factors in hematopoiesis
Hematopoiesis is a continuous process of blood cell production driven by hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. Proliferation and differentiation of HSPCs are regulated by complex transcriptional networks. In order to identify transcription factors with key roles in HSPC-mediated hematopoietic reconstitution, we developed an efficient and robust CRISPR/Cas9-based in vivo genetic screen. Using this experimental system, we identified the TFDP1 transcription factor to be essential for HSPC proliferation and post-transplant hematopoiesis. We further discovered that E2F4, an E2F transcription factor, serves as a binding partner of TFDP1 and is required for HSPC proliferation. Deletion of TFDP1 caused downregulation of genes associated with the cell cycle, with around 50% of these genes being identified as direct targets of TFDP1 and E2F4. Thus, our study expands the transcriptional network governing hematopoietic development through an in vivo CRISPR/Cas9-based genetic screen and identifies TFDP1/E2F4 as positive regulators of cell cycle genes in HSPCs.
- 23 July 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (9) , 2003-2015
Open AccessIn vivo CRISPR/Cas9-mediated screen reveals a critical function of TFDP1 and E2F4 transcription factors in hematopoiesis
Hematopoiesis is a continuous process of blood cell production driven by hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. Proliferation and differentiation of HSPCs are regulated by complex transcriptional networks. In order to identify transcription factors with key roles in HSPC-mediated hematopoietic reconstitution, we developed an efficient and robust CRISPR/Cas9-based in vivo genetic screen. Using this experimental system, we identified the TFDP1 transcription factor to be essential for HSPC proliferation and post-transplant hematopoiesis. We further discovered that E2F4, an E2F transcription factor, serves as a binding partner of TFDP1 and is required for HSPC proliferation. Deletion of TFDP1 caused downregulation of genes associated with the cell cycle, with around 50% of these genes being identified as direct targets of TFDP1 and E2F4. Thus, our study expands the transcriptional network governing hematopoietic development through an in vivo CRISPR/Cas9-based genetic screen and identifies TFDP1/E2F4 as positive regulators of cell cycle genes in HSPCs.
- 2 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (92) , eadi0042
Precise CRISPR-Cas9 gene repair in autologous memory T cells to treat familial hemophagocytic lymphohistiocytosis
Familial hemophagocytic lymphohistiocytosis (FHL) is an inherited, often fatal immune deficiency characterized by severe systemic hyperinflammation. Although allogeneic bone marrow transplantation can be curative, more effective therapies are urgently needed. FHL is caused by inactivating mutations in proteins that regulate cellular immunity. Here, we used an adeno-associated virus–based CRISPR-Cas9 system with an inhibitor of nonhomologous end joining to repair such mutations in potentially long-lived T cells ex vivo. Repaired CD8 memory T cells efficiently cured lethal hyperinflammation in a mouse model of Epstein-Barr virus–triggered FHL2, a subtype caused by perforin-1 ( Prf1 ) deficiency. Furthermore, repair of PRF1 and Munc13-4 ( UNC13D )—whose deficiency causes the FHL subtype FHL3—in mutant memory T cells from two critically ill patients with FHL restored T cell cytotoxicity. These results provide a starting point for the treatment of genetic T cell immune dysregulation syndromes with repaired autologous T cells.
- 2 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (92) , eadi0042
Precise CRISPR-Cas9 gene repair in autologous memory T cells to treat familial hemophagocytic lymphohistiocytosis
Familial hemophagocytic lymphohistiocytosis (FHL) is an inherited, often fatal immune deficiency characterized by severe systemic hyperinflammation. Although allogeneic bone marrow transplantation can be curative, more effective therapies are urgently needed. FHL is caused by inactivating mutations in proteins that regulate cellular immunity. Here, we used an adeno-associated virus–based CRISPR-Cas9 system with an inhibitor of nonhomologous end joining to repair such mutations in potentially long-lived T cells ex vivo. Repaired CD8 memory T cells efficiently cured lethal hyperinflammation in a mouse model of Epstein-Barr virus–triggered FHL2, a subtype caused by perforin-1 ( Prf1 ) deficiency. Furthermore, repair of PRF1 and Munc13-4 ( UNC13D )—whose deficiency causes the FHL subtype FHL3—in mutant memory T cells from two critically ill patients with FHL restored T cell cytotoxicity. These results provide a starting point for the treatment of genetic T cell immune dysregulation syndromes with repaired autologous T cells.
- Open Access
- 5 January 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1083119
A CRISPR/Cas9-mediated screen identifies determinants of early plasma cell differentiation
Introduction: The differentiation of B cells into antibody-secreting plasma cells depends on cell division-coupled, epigenetic and other cellular processes that are incompletely understood.Methods: We have developed a CRISPR/Cas9-based screen that models an early stage of T cell-dependent plasma cell differentiation and measures B cell survival or proliferation versus the formation of CD138+ plasmablasts. Here, we refined and extended this screen to more than 500 candidate genes that are highly expressed in plasma cells.Results: Among known genes whose deletion preferentially or mostly affected plasmablast formation were the transcription factors Prdm1 (BLIMP1), Irf4 and Pou2af1 (OBF-1), and the Ern1 gene encoding IRE1a, while deletion of XBP1, the transcriptional master regulator that specifies the expansion of the secretory program in plasma cells, had no effect. Defective plasmablast formation caused by Ern1 deletion could not be rescued by the active, spliced form of XBP1 whose processing is dependent on and downstream of IRE1a, suggesting that in early plasma cell differentiation IRE1a acts independently of XBP1. Moreover, we newly identified several genes involved in NF-kB signaling (Nfkbia), vesicle trafficking (Arf4, Preb) and epigenetic regulators that form part of the NuRD complex (Hdac1, Mta2, Mbd2) to be required for plasmablast formation. Deletion of ARF4, a small GTPase required for COPI vesicle formation, impaired plasmablast formation and blocked antibody secretion. After Hdac1 deletion plasmablast differentiation was consistently reduced by about 50%, while deletion of the closely related Hdac2 gene had no effect. Hdac1 knock-out led to strongly perturbed protein expression of antagonistic transcription factors that govern plasma cell versus B cell identity (by decreasing IRF4 and BLIMP1 and increasing BACH2 and PAX5).Discussion: Taken together, our results highlight specific and non-redundant roles for Ern1, Arf4 and Hdac1 in the early steps of plasma cell differentiation.
- 5 January 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1083119
Open AccessA CRISPR/Cas9-mediated screen identifies determinants of early plasma cell differentiation
Introduction: The differentiation of B cells into antibody-secreting plasma cells depends on cell division-coupled, epigenetic and other cellular processes that are incompletely understood.Methods: We have developed a CRISPR/Cas9-based screen that models an early stage of T cell-dependent plasma cell differentiation and measures B cell survival or proliferation versus the formation of CD138+ plasmablasts. Here, we refined and extended this screen to more than 500 candidate genes that are highly expressed in plasma cells.Results: Among known genes whose deletion preferentially or mostly affected plasmablast formation were the transcription factors Prdm1 (BLIMP1), Irf4 and Pou2af1 (OBF-1), and the Ern1 gene encoding IRE1a, while deletion of XBP1, the transcriptional master regulator that specifies the expansion of the secretory program in plasma cells, had no effect. Defective plasmablast formation caused by Ern1 deletion could not be rescued by the active, spliced form of XBP1 whose processing is dependent on and downstream of IRE1a, suggesting that in early plasma cell differentiation IRE1a acts independently of XBP1. Moreover, we newly identified several genes involved in NF-kB signaling (Nfkbia), vesicle trafficking (Arf4, Preb) and epigenetic regulators that form part of the NuRD complex (Hdac1, Mta2, Mbd2) to be required for plasmablast formation. Deletion of ARF4, a small GTPase required for COPI vesicle formation, impaired plasmablast formation and blocked antibody secretion. After Hdac1 deletion plasmablast differentiation was consistently reduced by about 50%, while deletion of the closely related Hdac2 gene had no effect. Hdac1 knock-out led to strongly perturbed protein expression of antagonistic transcription factors that govern plasma cell versus B cell identity (by decreasing IRF4 and BLIMP1 and increasing BACH2 and PAX5).Discussion: Taken together, our results highlight specific and non-redundant roles for Ern1, Arf4 and Hdac1 in the early steps of plasma cell differentiation.
- Open Access
- 1 January 2023
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 13 (8)
Application of a Spacer-nick Gene-targeting Approach to Repair Disease-causing Mutations with Increased Safety
The CRISPR/Cas9 system is a powerful tool for gene repair that holds great potential for gene therapy to cure monogenic diseases. Despite intensive improvement, the safety of this system remains a major clinical concern. In contrast to Cas9 nuclease, Cas9 nickases with a pair of short-distance (38-68 bp) PAM-out single-guide RNAs (sgRNAs) preserve gene repair efficiency while strongly reducing off-target effects. However, this approach still leads to efficient unwanted on-target mutations that may cause tumorigenesis or abnormal hematopoiesis. We establish a precise and safe spacer-nick gene repair approach that combines Cas9(D10A) nickase with a pair of PAM-out sgRNAs at a distance of 200-350 bp. In combination with adeno-associated virus (AAV) serotype 6 donor templates, this approach leads to efficient gene repair with minimal unintended on- and off-target mutations in human hematopoietic stem and progenitor cells (HSPCs). Here, we provide detailed protocols to use the spacer-nick approach for gene repair and to assess the safety of this system in human HSPCs. The spacer-nick approach enables efficient gene correction for repair of disease-causing mutations with increased safety and suitability for gene therapy.
- 1 January 2023
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 13 (8)
Open AccessApplication of a Spacer-nick Gene-targeting Approach to Repair Disease-causing Mutations with Increased Safety
The CRISPR/Cas9 system is a powerful tool for gene repair that holds great potential for gene therapy to cure monogenic diseases. Despite intensive improvement, the safety of this system remains a major clinical concern. In contrast to Cas9 nuclease, Cas9 nickases with a pair of short-distance (38-68 bp) PAM-out single-guide RNAs (sgRNAs) preserve gene repair efficiency while strongly reducing off-target effects. However, this approach still leads to efficient unwanted on-target mutations that may cause tumorigenesis or abnormal hematopoiesis. We establish a precise and safe spacer-nick gene repair approach that combines Cas9(D10A) nickase with a pair of PAM-out sgRNAs at a distance of 200-350 bp. In combination with adeno-associated virus (AAV) serotype 6 donor templates, this approach leads to efficient gene repair with minimal unintended on- and off-target mutations in human hematopoietic stem and progenitor cells (HSPCs). Here, we provide detailed protocols to use the spacer-nick approach for gene repair and to assess the safety of this system in human HSPCs. The spacer-nick approach enables efficient gene correction for repair of disease-causing mutations with increased safety and suitability for gene therapy.
- Open Access
- 3 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (22) , eabm9106
Precise CRISPR-Cas–mediated gene repair with minimal off-target and unintended on-target mutations in human hematopoietic stem cells
While CRISPR-Cas9 is key for the development of gene therapy, its potential off-target mutations are still a major concern. Here, we establish a “spacer-nick” gene correction approach that combines the Cas9 D10A nickase with a pair of PAM-out sgRNAs at a distance of 200 to 350 bp. In combination with adeno-associated virus (AAV) serotype 6 template delivery, our approach led to efficient HDR in human hematopoietic stem and progenitor cells (HSPCs including long-term HSCs) and T cells, with minimal NHEJ-mediated on-target mutations. Using spacer-nick, we developed an approach to repair disease-causing mutations occurring in the HBB , ELANE , IL7R , and PRF1 genes. We achieved gene correction efficiencies of 20 to 50% with minimal NHEJ-mediated on-target mutations. On the basis of in-depth off-target assessment, frequent unintended genetic alterations induced by classical CRISPR-Cas9 were significantly reduced or absent in the HSPCs treated with spacer-nick. Thus, the spacer-nick gene correction approach provides improved safety and suitability for gene therapy.
- 3 June 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (22) , eabm9106
Open AccessPrecise CRISPR-Cas–mediated gene repair with minimal off-target and unintended on-target mutations in human hematopoietic stem cells
While CRISPR-Cas9 is key for the development of gene therapy, its potential off-target mutations are still a major concern. Here, we establish a “spacer-nick” gene correction approach that combines the Cas9 D10A nickase with a pair of PAM-out sgRNAs at a distance of 200 to 350 bp. In combination with adeno-associated virus (AAV) serotype 6 template delivery, our approach led to efficient HDR in human hematopoietic stem and progenitor cells (HSPCs including long-term HSCs) and T cells, with minimal NHEJ-mediated on-target mutations. Using spacer-nick, we developed an approach to repair disease-causing mutations occurring in the HBB , ELANE , IL7R , and PRF1 genes. We achieved gene correction efficiencies of 20 to 50% with minimal NHEJ-mediated on-target mutations. On the basis of in-depth off-target assessment, frequent unintended genetic alterations induced by classical CRISPR-Cas9 were significantly reduced or absent in the HSPCs treated with spacer-nick. Thus, the spacer-nick gene correction approach provides improved safety and suitability for gene therapy.
- Open Access
- 1 December 2020
- Published by Elsevier in Molecular Therapy
- Vol. 28 (12) , 2621-2634
CRISPR-Cas9-Mediated ELANE Mutation Correction in Hematopoietic Stem and Progenitor Cells to Treat Severe Congenital Neutropenia
- 1 December 2020
- Published by Elsevier in Molecular Therapy
- Vol. 28 (12) , 2621-2634
Open AccessCRISPR-Cas9-Mediated ELANE Mutation Correction in Hematopoietic Stem and Progenitor Cells to Treat Severe Congenital Neutropenia
- Open Access
- 1 June 2020
- Published by Elsevier in STAR Protocols
- Vol. 1 (1) , 100028
Protocol for Efficient CRISPR/Cas9/AAV-Mediated Homologous Recombination in Mouse Hematopoietic Stem and Progenitor Cells
- 1 June 2020
- Published by Elsevier in STAR Protocols
- Vol. 1 (1) , 100028
Open AccessProtocol for Efficient CRISPR/Cas9/AAV-Mediated Homologous Recombination in Mouse Hematopoietic Stem and Progenitor Cells
- Open Access
- 1 September 2019
- Published by Elsevier in Cell Reports
- Vol. 28 (13) , 3510-3522.e5
Efficient CRISPR/Cas9-Mediated Gene Knockin in Mouse Hematopoietic Stem and Progenitor Cells
- 1 September 2019
- Published by Elsevier in Cell Reports
- Vol. 28 (13) , 3510-3522.e5
Open AccessEfficient CRISPR/Cas9-Mediated Gene Knockin in Mouse Hematopoietic Stem and Progenitor Cells